Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives $25.20 Consensus Price Target from Analysts

Posted by Alanna Baker on Jun 17th, 2026

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN – Get Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $25.20.

Several research firms have recently commented on EIKN. Wall Street Zen downgraded Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. JPMorgan Chase & Co. began coverage on Eikon Therapeutics in a report on Monday, March 2nd. They set an “overweight” rating and a $29.00 price objective for the company. Morgan Stanley began coverage on Eikon Therapeutics in a report on Monday, March 2nd. They set an “overweight” rating and a $32.00 price objective for the company. Weiss Ratings began coverage on Eikon Therapeutics in a report on Monday, June 1st. They set a “sell (e-)” rating for the company. Finally, Bank of America began coverage on Eikon Therapeutics in a report on Monday, March 2nd. They set a “buy” rating and a $34.00 price objective for the company.

View Our Latest Research Report on EIKN

Eikon Therapeutics Trading Down 2.8%

Shares of EIKN opened at $9.07 on Wednesday. Eikon Therapeutics has a 52-week low of $7.90 and a 52-week high of $17.40. The firm has a 50 day simple moving average of $10.18.

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($26.23) EPS for the quarter.

Eikon Therapeutics Company Profile

(Get Free Report)

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.